Akili raises extra $13M ahead of FDA decision on prescription video game for ADHD

Akili recently filed for 510(k) clearance for its prescription, tablet-based video game for ADHD after it met its endpoint in a randomized trial in December 2017. (Akili)

Akili Interactive has gathered an additional $13 million to fund its prescription video game treatments, bringing its series C total up to $68 million. Meanwhile, it is awaiting an FDA clearance decision on its recently filed digital therapeutic for pediatric ADHD.

Launched in May, the initial round was led by Temasek and included Amgen Ventures and M Ventures, the VC fund of Merck KGaA, as well as Baillie Gifford, JAZZ Venture Partners, Canepa Advanced Healthcare Fund and Brooklands Capital Strategies.

The Boston-based company’s latest investors were CLSA, Omidyar Technology Ventures, Fearless Ventures and Digital Garage Group, which includes DG Incubation and DG Daiwa Ventures.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Both Akili and the broader field of digital medicine have been advancing at a significant pace,” Akili CEO Eddie Martucci, Ph.D., said in a statement. If cleared by the agency, the company’s lead product, AKL-T01, would be the first prescription video game and the first digital medicine for children with ADHD.

RELATED: Akili's video game therapy hits goal in pivotal ADHD trial

“This additional backing from investors will help us significantly drive forward the development and deployment of our technology platform toward our goal of having a major impact in millions of patients and toward fulfilling the immense promise of digital medicine,” Martucci said.

In clinical trial results posted last December, Akili’s tablet-based video game improved attention and control in children ages eight to 12 with ADHD after four weeks, compared to children who played a different game without embedded stimuli designed to engage specific areas of the brain.

Akili is also developing interactive, digital treatments in major depressive disorder, autism spectrum disorder, multiple sclerosis and inflammatory diseases, and anticipates phase 2 results in MDD by the end of the year.

Suggested Articles

The FDA has approved its first contact lens designed to effectively slow the progression of nearsightedness in children, starting in ages 8 to 12.

Novartis tapped Biofourmis to develop tracking programs for heart failure patients, as the latter acquired Biovotion, makers of clinical wearables.

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.